Barreby, Emelie https://orcid.org/0000-0002-6467-5280
Strunz, Benedikt
Nock, Sebastian https://orcid.org/0000-0001-5224-0047
Naudet, Léa
Shen, Joanne X.
Johansson, Helene
Sönnerborg, Isabella
Ma, Junjie
Urgard, Egon
Pallett, Laura J. https://orcid.org/0000-0002-4161-9462
Hu, Yizhou https://orcid.org/0000-0002-2635-0258
Fardellas, Achilleas https://orcid.org/0000-0003-2797-6962
Azzimato, Valerio https://orcid.org/0000-0003-4141-961X
Vankova, Ana https://orcid.org/0000-0003-0955-8097
Levi, Laura
Morgantini, Cecilia https://orcid.org/0000-0003-3142-2508
Maini, Mala K. https://orcid.org/0000-0001-6384-1462
Stål, Per
Rosshart, Stephan P. https://orcid.org/0000-0002-6989-8686
Coquet, Jonathan M. https://orcid.org/0000-0002-5967-4857
Nowak, Greg https://orcid.org/0000-0001-8766-8860
Näslund, Erik https://orcid.org/0000-0002-0166-6344
Lauschke, Volker M. https://orcid.org/0000-0002-1140-6204
Ellis, Ewa https://orcid.org/0000-0002-3057-5337
Björkström, Niklas K. https://orcid.org/0000-0002-0967-076X
Chen, Ping https://orcid.org/0000-0002-8068-1891
Aouadi, Myriam https://orcid.org/0000-0001-6256-7107
Article History
Received: 9 December 2021
Accepted: 5 June 2023
First Online: 6 July 2023
Competing interests
: V.M.L. is founder, CEO and shareholder of HepaPredict AB. In addition, V.M.L. discloses consultancy work for EnginZyme AB. The remaining authors declare no competing interests.